Qiagen Sees Unusually High Options Volume (NYSE:QGEN)

Qiagen N.V. (NYSE:QGEN) saw unusually large options trading on Thursday. Stock investors acquired 5,826 call options on the stock. This is an increase of 94% compared to the average volume of 2,999 call options.

Analyst Upgrades and Downgrades

QGEN has been the subject of several research reports. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $52.00 price target (down from $55.00) on shares of Qiagen in a report on Thursday. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price target on shares of Qiagen in a research note on Thursday, August 6th. UBS Group assumed coverage on Qiagen in a report on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 price objective on the stock. Stifel Nicolaus set a $40.00 price objective on Qiagen in a report on Friday, August 7th. Finally, Robert W. Baird raised their price objective on shares of Qiagen from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday. Four research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $44.43.

Key Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: EQT takeover agreement: EQT agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per outstanding share. The deal provides a substantial transaction premium and is the main catalyst behind the stock’s advance. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Solid preliminary Q3 performance: Qiagen reported preliminary revenue of $548 million and adjusted diluted EPS of $0.65, both at constant exchange rates. The company is scheduled to release complete third-quarter results on November 4. QIAGEN reports preliminary Q3 2026 results
• Neutral Sentiment: Mixed analyst revisions: Robert W. Baird raised its price target from $50 to $52 and upgraded Qiagen to “outperform,” indicating modest additional upside. JPMorgan reaffirmed its “neutral” rating but reduced its target from $55 to $52, suggesting a more limited valuation opportunity after the recent rally.
• Neutral Sentiment: Deal-related trading considerations: With the stock trading near the reported takeover value, further gains may depend on completion of the transaction rather than operating performance. Investors should monitor shareholder and regulatory approvals, as well as any changes to the offer terms.

Qiagen Stock Up 0.5%

NYSE QGEN traded up $0.26 during trading on Thursday, hitting $50.26. 25,070,328 shares of the company traded hands, compared to its average volume of 2,643,018. The business has a fifty day simple moving average of $44.15 and a 200 day simple moving average of $40.51. The company has a current ratio of 2.85, a quick ratio of 2.31 and a debt-to-equity ratio of 0.48. Qiagen has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a market capitalization of $10.36 billion, a P/E ratio of 25.75, a PEG ratio of 4.87 and a beta of 0.61.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The firm had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. During the same period in the previous year, the company earned $0.60 EPS. The company’s revenue for the quarter was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, sell-side analysts predict that Qiagen will post 2.43 EPS for the current year.

Hedge Funds Weigh In On Qiagen

Several large investors have recently bought and sold shares of the stock. Crossmark Global Holdings Inc. acquired a new position in Qiagen in the 3rd quarter valued at approximately $363,000. Quadrant Capital Group LLC lifted its holdings in shares of Qiagen by 2.4% during the third quarter. Quadrant Capital Group LLC now owns 42,660 shares of the company’s stock valued at $1,938,000 after acquiring an additional 1,003 shares during the period. Nisa Investment Advisors LLC boosted its position in Qiagen by 61.4% in the third quarter. Nisa Investment Advisors LLC now owns 7,533 shares of the company’s stock valued at $330,000 after buying an additional 2,867 shares in the last quarter. Cordatus Wealth Management LLC acquired a new position in shares of Qiagen in the 3rd quarter worth approximately $678,000. Finally, Assenagon Asset Management S.A. boosted its stake in Qiagen by 1.9% in the third quarter. Assenagon Asset Management S.A. now owns 15,722 shares of the company’s stock worth $691,000 after purchasing an additional 286 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.